Hyrax Biosciences

Executive Summary

Hyrax Biosciences is a South African bioinformatics company specializing in software for genomic data analysis, with a primary focus on antimicrobial resistance (AMR) and infectious disease diagnostics. Founded in 2013 and based in Cape Town, the company leverages AI and machine learning to enable rapid, accurate detection of resistance markers and pathogen identification. Its platform technology is designed to integrate with sequencing workflows, offering scalable solutions for clinical and public health settings. While the company remains privately held and has not disclosed funding or valuation, its positioning in the growing AMR diagnostics market—estimated to reach $5 billion by 2027—underscores its potential. Hyrax's platform approach, combined with a lean operational model (10-50 employees), allows for agile product development and partnerships. The company is expected to capitalize on increasing global demand for genomic surveillance tools, particularly in low- and middle-income countries where AMR burden is high. With no disclosed revenue or commercial products yet, Hyrax is at an inflection point where successful execution on near-term milestones could unlock significant value.

Upcoming Catalysts (preview)

• Q3 2026Launch of cloud-based AMR detection platform with real-time analytics60% success
• Q4 2026Strategic partnership with a global health organization (e.g., FIND or WHO) for AMR surveillance70% success
• Q2 2026Regulatory clearance (CE-IVD or SAHPRA) for a diagnostic test based on its software50% success